Tirzepatide ODT — Dual GIP/GLP-1 Oral Weight Loss | Newfield Health

Compounded medication notice: Tirzepatide ODT is a compounded prescription medication. It is not FDA-approved. There are currently no FDA-approved oral tirzepatide products. A licensed provider determines whether this medication is appropriate after reviewing your health history.

Weight Loss · Dual GIP/GLP-1 · Compounded

Two appetite pathways.
One oral formulation.

Tirzepatide activates both GLP-1 and GIP receptor pathways — a dual mechanism for appetite regulation. This compounded orally disintegrating tablet offers a non-injectable option for qualified candidates.

Start your free intake →
Compounded — not FDA-approved No injection required Provider review required
DualGIP + GLP-1 pathways
ODTOral disintegrating tablet
OralNo injection required
Rx onlyProvider approval required
Why tirzepatide

Two pathways instead of one

Most GLP-1 medications activate a single receptor pathway. Tirzepatide activates two: GLP-1 and GIP. This dual mechanism is what distinguishes tirzepatide from semaglutide as a class.

GIP — glucose-dependent insulinotropic polypeptide — plays a role in fat metabolism and may enhance the appetite-regulating effects of GLP-1 activation. The combination has shown additive effects on appetite reduction.

Tirzepatide ODT is a compounded oral disintegrating tablet — not injectable, and not an FDA-approved product. There are currently no FDA-approved oral tirzepatide products. Clinical trial results from injectable tirzepatide do not apply to this oral dosage form.

The dual mechanism
"Tirzepatide activates both GLP-1 and GIP pathways — the combination that distinguishes it from single-pathway GLP-1 medications."
Results from FDA-approved injectable tirzepatide do not apply to this compounded oral formulation. Your provider will explain this distinction clearly.
How it works

The dual pathway
explained

Tirzepatide simultaneously activates two distinct receptor systems involved in appetite regulation and metabolic signaling.

Pathway 1
GLP-1 Receptor Activation
Signals fullness, slows gastric emptying, reduces appetite, and supports blood sugar regulation.
Pathway 2
GIP Receptor Activation
Influences fat metabolism and may enhance the appetite-regulating effects of GLP-1 activation.

About this formulation: This description applies to tirzepatide as a class. The compounded ODT is a different dosage form than the injectable studied in trials. Absorption and efficacy may differ.

Compare options

Other weight loss treatments

Not sure which option is right for you? Your physician will help determine the best fit based on your metabolic profile.

Metformin

Metabolic foundation · Oral tablet · FDA-approved

Learn more →

Semaglutide Oral Suspension

GLP-1 · Reduces appetite · Compounded oral

Learn more →

Tirzepatide ODT

Dual GIP/GLP-1 · Compounded oral disintegrating tablet

Current selection
What to expect

A realistic timeline

Weeks 1–8
Dose introduction & tolerance

Your provider will start at a low dose and titrate upward. GI side effects are common during this window. Appetite changes may begin to appear as the dose increases.

Months 3–6
Appetite stabilization

GI effects typically ease at a stable dose. Appetite reduction becomes more consistent. Weight effects follow appetite change.

Months 6–12+
Protocol evaluation

Your provider evaluates your response and may adjust the protocol. Long-term maintenance planning begins in this window.

The most important expectation to set

Published weight loss results for tirzepatide are from FDA-approved injectable tirzepatide in clinical trials. This compounded ODT is a different dosage form. Outcomes may differ materially. Your provider will be direct about expectations.

Questions

What patients ask about
Tirzepatide ODT

Is this the same as Zepbound or Mounjaro?
No. Zepbound and Mounjaro are FDA-approved injectable tirzepatide products. This is a compounded oral disintegrating tablet — not injectable, not FDA-approved, and not studied to the same standard.
Is there an FDA-approved oral tirzepatide?
No — as of 2026, there are no FDA-approved oral tirzepatide products. All FDA-approved tirzepatide is injectable.
Will I get the same results as Zepbound?
Not necessarily. The published results are from injectable Zepbound in clinical trials. This oral formulation has different absorption characteristics. Your provider will set realistic expectations.
What if my provider recommends metformin instead?
Your provider may determine metformin is a more appropriate starting point. The program covers provider access regardless of which medication is prescribed.
Do I still need to change my diet?
Yes. Appetite reduction works best when paired with dietary adjustment. The medication changes the hunger signal — it does not eliminate the need for behavioral changes.
What side effects should I expect?
Common side effects include nausea, vomiting, diarrhea, and decreased appetite — most pronounced during dose titration. Your provider will monitor your response closely.

Two appetite pathways.
No injection required.

If you're interested in a dual GIP/GLP-1 oral option and your provider determines this approach is clinically appropriate.

Start your free intake →

Important Safety Information

Compounded medication — not FDA-approved. No FDA-approved oral tirzepatide product exists. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN syndrome type 2. Common side effects: nausea, vomiting, diarrhea. This information does not constitute medical advice. Provider review required.